The toripalimab India approval for advanced esophageal cancer adds a second indication to a drug that Dr. Reddy’s Laboratories has been building as an oncology franchise in India. According to the company’s disclosure, reported on 21 October 2026, the regulator approved toripalimab, sold as Zytorvi, with cisplatin and paclitaxel as first-line treatment for eligible adults with advanced, recurrent or metastatic esophageal squamous cell carcinoma. This industry report looks at what the approval says about the company’s strategy, what the supporting trial data show, and which commercial questions the announcement leaves open. It is not investment advice.
Toripalimab India approval: key takeaways
- The approval is Zytorvi’s second Indian indication, after nasopharyngeal carcinoma, for which Dr. Reddy’s launched the drug in November 2024.
- It is reported to be used without PD-L1 testing for patient selection.
- The supporting JUPITER-06 trial showed median overall survival of 17.7 months versus 12.9 months, a hazard ratio of 0.72, per the licensor’s release.
- Dr. Reddy’s licensed the drug from Junshi Biosciences in 2023 for 21 countries including India, as reported.
- Price, launch date, sales expectations and the approval date have not been disclosed.
What the toripalimab India approval covers
Reports of the company’s disclosure say the Central Drugs Standard Control Organisation, under the Drugs Controller General of India, approved Zytorvi for first-line use with chemotherapy in adults with unresectable, advanced, recurrent or metastatic esophageal squamous cell carcinoma, and that patient selection does not require PD-L1 testing. We have not seen the label or the regulator’s documents, which would appear on the Central Drugs Standard Control Organisation site, so we rely on the reported description. M.V. Ramana, chief executive of Global Generics at Dr. Reddy’s, called the approval a crucial advancement in extending immunotherapy options to patients.
The franchise behind the toripalimab India approval
According to the reports, Dr. Reddy’s licensed toripalimab from Junshi Biosciences in 2023, with exclusive rights to develop and market it in 21 countries including India. Its first Indian approval was for nasopharyngeal carcinoma, and the company announced the launch in November 2024, as its Dr. Reddy’s launch announcement of November 2024 described it. Seen together, the sequence is a licensor-developed drug entering India through successive indications, which is a common route for in-licensed oncology products. This reading is our analysis, and the company has not set out sales targets or a roadmap in the material we reviewed.
Trial data behind the toripalimab India approval
The evidence base is the JUPITER-06 Phase 3 trial, in which 514 previously untreated patients at 72 centres in China received toripalimab or placebo with paclitaxel and cisplatin. In its Junshi Biosciences’ release on the final analysis, Junshi reports final median overall survival of 17.7 months versus 12.9 months, a hazard ratio of 0.72 and three-year survival of 29.7% versus 19.9%. The original Cancer Cell publication reported a progression-free survival hazard ratio of 0.58, the source of the 42% risk-reduction figure in some reports; that figure concerns progression and not survival.
Safety profile in the toripalimab India approval
In the original report, serious treatment-emergent adverse events of grade 3 or higher occurred in 73.2% of patients on toripalimab and 70.0% on placebo, with fatal events at 8.2% in both arms. Immune-related adverse events were more common with toripalimab, at 37.0% versus 26.5%. Junshi says long-term follow-up showed no new safety signals. These points matter commercially because immune-related side effects require monitoring capacity at treating centres.
Commercial questions the approval leaves open
This section is our analysis. The reports give no price, launch date or access programme, and those will shape uptake as much as the clinical data. Cancer drugs in India are often paid for out of pocket, so patient access programmes, tiered pricing and hospital partnerships can matter greatly. Another question is whether physicians will adopt a PD-L1-independent regimen quickly, given that the pivotal trial enrolled Chinese patients only. We cannot estimate sales and make no forecast.
Why the toripalimab India approval has a PD-L1-independent label
This section is general background and our analysis. Some immunotherapy labels depend on a biomarker test, which adds cost, time and a step that can exclude patients when tissue samples are limited. A label that reportedly does not require PD-L1 testing removes that step, which may simplify prescribing at smaller centres. The JUPITER-06 investigators reported benefit across PD-L1 subgroups, which is the evidence usually cited for such a label. Whether Indian oncologists will treat all eligible patients or still favour tested patients is something only prescribing patterns will reveal.
How the toripalimab India approval fits Indian regulation
General background: new drugs and new indications in India are reviewed by the national regulator, which may ask for local data or accept foreign trial evidence depending on the case. The reports say this approval followed the company’s application, but they do not describe the review, any local trial requirement or conditions attached to the approval. We therefore make no claim about them.
The competitive picture after the toripalimab India approval
We did not compile a list of competing esophageal cancer treatments in India and make no claim about which rivals are marketed, priced or reimbursed. Readers who follow the sector should note that the reports describe the approval as extending immunotherapy options, and that the practical competition for a first-line regimen is the existing chemotherapy-based standard of care, against which JUPITER-06 was designed.
What the toripalimab India approval leaves undisclosed
- The approval date and the label text.
- Pricing, launch timing and access arrangements.
- Any India-specific study or post-approval commitments.
- Financial terms of the Junshi licence.
Risks and caveats on the toripalimab India approval
- Trial figures are from a trial in Chinese patients, and the final analysis comes from a company release.
- Reports of the approval differ in detail and we have not seen the label.
- Our reading of the company’s strategy is analysis, not a company statement.
- This is news reporting, not investment, medical or legal advice.
In our assessment, the toripalimab India approval strengthens Dr. Reddy’s oncology position on paper, but whether it becomes a meaningful product depends on price, access and clinician adoption, none of which the announcement addresses. See also AstraZeneca Pays $40 Million Upfront in AI Pact With insitro. More in our pharmaceuticals coverage.
What to watch next on the toripalimab India approval
- Launch date, pricing and patient-access programmes.
- Publication of the final survival analysis in a peer-reviewed journal.
- Further indications for toripalimab in India.
Frequently asked questions
What did the regulator approve?
Zytorvi (toripalimab) with cisplatin and paclitaxel as first-line treatment for eligible adults with advanced, recurrent or metastatic esophageal squamous cell carcinoma, per the company disclosure as reported.
Is this Zytorvi’s first Indian approval?
No. It is the second, after nasopharyngeal carcinoma.
Who developed toripalimab?
Junshi Biosciences, which licensed it to Dr. Reddy’s in 2023 for 21 countries including India, according to the reports.
Has the price been announced?
Not in the reports we reviewed. Price, launch timing and access programmes remain undisclosed.
How we reported this: we relied on reports of the company’s disclosure of 21 October 2026, the licensor’s release, the JUPITER-06 publication and the November 2024 launch announcement. Our analysis is labelled. Last updated: 21 October 2026. This article is news reporting and not investment, medical or legal advice.
